阿法替尼是一种新型的低分子量人类表皮生长因子受体(human epidermal growth factor receptor, HER)家族抑制剂,它属于第二代表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs),在临床前和临床研究中显示了该药对具有表皮生长因子受体(epidermal growth factor receptor, EGFR)活性突变的非小细胞肺癌(non-small cell lung cancer, NSCLC)的疗效。本研究关注阿法替尼治疗晚期肺腺癌患者的安全性。. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.